The Future of Systemic Lupus Erythematosus Treatment: The Promise of Selective Immunotherapies, Anifrolumab and Belimumab, Compared to Blanket Immunosuppressives

Recent research indicates that selective immunotherapies, such as anifrolumab and belimumab, are more effective in managing systemic lupus erythematosus (SLE) compared to traditional blanket immunosuppressive drugs. Anifrolumab targets type I interferons, while belimumab neutralizes BLyS to reduce autoantibody production, addressing the root cause of SLE rather than just alleviating symptoms. This paper discusses the immunology of SLE, compares traditional and selective treatments, and reviews clinical trial results for these newer therapies.